Citigroup Inc. set a GBX 6,000 ($77.49) price target on AstraZeneca plc (LON:AZN) in a research report released on Wednesday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

AZN has been the topic of several other research reports. HSBC Holdings plc reaffirmed a reduce rating and issued a GBX 4,100 ($52.95) target price on shares of AstraZeneca plc in a research report on Monday, September 11th. UBS AG set a GBX 5,150 ($66.51) target price on AstraZeneca plc and gave the company a neutral rating in a research report on Tuesday, June 27th. BNP Paribas set a GBX 5,300 ($68.45) target price on AstraZeneca plc and gave the company a neutral rating in a research report on Monday, September 11th. Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($50.37) target price on AstraZeneca plc and gave the company a sell rating in a research report on Saturday, May 20th. Finally, Barclays PLC reaffirmed an overweight rating and issued a GBX 5,500 ($71.03) target price on shares of AstraZeneca plc in a research report on Tuesday, August 1st. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have assigned a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus target price of GBX 5,022.91 ($64.87).

Shares of AstraZeneca plc (LON AZN) opened at 4719.50 on Wednesday. The company’s market cap is GBX 59.75 billion. The firm has a 50 day moving average price of GBX 4,556.15 and a 200-day moving average price of GBX 4,880.61. AstraZeneca plc has a 12 month low of GBX 3,996.00 and a 12 month high of GBX 5,520.00.

TRADEMARK VIOLATION NOTICE: This article was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/citigroup-inc-analysts-give-astrazeneca-plc-azn-a-gbx-6000-price-target/1565575.html.

The business also recently declared a dividend, which was paid on Monday, September 11th. Investors of record on Thursday, August 10th were paid a GBX 68.90 ($0.89) dividend. This represents a dividend yield of 1.35%. The ex-dividend date was Thursday, August 10th.

In related news, insider Nazneen Rahman purchased 39 shares of the business’s stock in a transaction that occurred on Thursday, July 27th. The stock was acquired at an average cost of GBX 4,370 ($56.44) per share, for a total transaction of £1,704.30 ($2,201.08).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.